nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—CA2—osteoporosis	0.286	1	CbGaD
Imatinib—CA14—Zoledronate—osteoporosis	0.0846	0.196	CbGbCtD
Imatinib—CA12—Zoledronate—osteoporosis	0.0601	0.139	CbGbCtD
Imatinib—CA2—Zoledronate—osteoporosis	0.0486	0.113	CbGbCtD
Imatinib—SLC22A1—Estropipate—osteoporosis	0.032	0.0741	CbGbCtD
Imatinib—ALB—Estropipate—osteoporosis	0.0187	0.0434	CbGbCtD
Imatinib—SLC22A2—Estradiol—osteoporosis	0.0153	0.0354	CbGbCtD
Imatinib—SLC22A1—Estradiol—osteoporosis	0.0133	0.0308	CbGbCtD
Imatinib—ABCG2—Conjugated Estrogens—osteoporosis	0.0128	0.0298	CbGbCtD
Imatinib—ABCG2—Estradiol—osteoporosis	0.0113	0.0261	CbGbCtD
Imatinib—CYP1A2—Estropipate—osteoporosis	0.0112	0.026	CbGbCtD
Imatinib—CYP2C9—Estropipate—osteoporosis	0.0101	0.0234	CbGbCtD
Imatinib—CYP3A7—Estradiol—osteoporosis	0.00833	0.0193	CbGbCtD
Imatinib—CYP3A7-CYP3A51P—Estradiol—osteoporosis	0.00833	0.0193	CbGbCtD
Imatinib—ALB—Estradiol—osteoporosis	0.00777	0.018	CbGbCtD
Imatinib—ABCB1—Ethinyl Estradiol—osteoporosis	0.00631	0.0146	CbGbCtD
Imatinib—CYP2C19—Cholecalciferol—osteoporosis	0.00625	0.0145	CbGbCtD
Imatinib—CYP3A5—Estradiol—osteoporosis	0.00625	0.0145	CbGbCtD
Imatinib—CYP3A4—Estropipate—osteoporosis	0.00587	0.0136	CbGbCtD
Imatinib—CYP3A4—Calcitriol—osteoporosis	0.00587	0.0136	CbGbCtD
Imatinib—CYP1A2—Conjugated Estrogens—osteoporosis	0.0053	0.0123	CbGbCtD
Imatinib—CYP2C9—Cholecalciferol—osteoporosis	0.0052	0.0121	CbGbCtD
Imatinib—CYP2C19—Estradiol—osteoporosis	0.00504	0.0117	CbGbCtD
Imatinib—CYP2D6—Cholecalciferol—osteoporosis	0.00475	0.011	CbGbCtD
Imatinib—CYP3A4—Ergocalciferol—osteoporosis	0.00469	0.0109	CbGbCtD
Imatinib—CYP1A2—Estradiol—osteoporosis	0.00465	0.0108	CbGbCtD
Imatinib—ABCB1—Conjugated Estrogens—osteoporosis	0.00463	0.0107	CbGbCtD
Imatinib—CYP2C9—Estradiol—osteoporosis	0.00419	0.00971	CbGbCtD
Imatinib—ABCB1—Estradiol—osteoporosis	0.00407	0.00943	CbGbCtD
Imatinib—CYP3A4—Raloxifene—osteoporosis	0.00391	0.00908	CbGbCtD
Imatinib—CYP3A4—Ethinyl Estradiol—osteoporosis	0.00378	0.00877	CbGbCtD
Imatinib—CYP3A4—Cholecalciferol—osteoporosis	0.00302	0.00701	CbGbCtD
Imatinib—CYP3A4—Conjugated Estrogens—osteoporosis	0.00277	0.00643	CbGbCtD
Imatinib—CSF1R—periosteum—osteoporosis	0.00249	0.184	CbGeAlD
Imatinib—CYP3A4—Estradiol—osteoporosis	0.00244	0.00565	CbGbCtD
Imatinib—ORM1—vertebral column—osteoporosis	0.00171	0.127	CbGeAlD
Imatinib—CA2—periosteum—osteoporosis	0.00134	0.0988	CbGeAlD
Imatinib—Nilotinib—CA2—osteoporosis	0.000977	1	CrCbGaD
Imatinib—ABL1—Levorphanol—Estradiol—osteoporosis	0.000891	1	CbGdCrCtD
Imatinib—DDR1—uterus—osteoporosis	0.000854	0.063	CbGeAlD
Imatinib—CA3—uterus—osteoporosis	0.000503	0.0372	CbGeAlD
Imatinib—LCK—uterus—osteoporosis	0.000468	0.0345	CbGeAlD
Imatinib—PIP4K2C—bone marrow—osteoporosis	0.000448	0.033	CbGeAlD
Imatinib—CA3—bone marrow—osteoporosis	0.000427	0.0315	CbGeAlD
Imatinib—LCK—bone marrow—osteoporosis	0.000397	0.0293	CbGeAlD
Imatinib—NQO2—uterus—osteoporosis	0.000387	0.0286	CbGeAlD
Imatinib—PDGFRA—uterus—osteoporosis	0.000386	0.0285	CbGeAlD
Imatinib—CSF1R—uterus—osteoporosis	0.00034	0.0251	CbGeAlD
Imatinib—NQO2—bone marrow—osteoporosis	0.000329	0.0243	CbGeAlD
Imatinib—SLC47A1—uterus—osteoporosis	0.000311	0.0229	CbGeAlD
Imatinib—KIT—uterus—osteoporosis	0.000309	0.0228	CbGeAlD
Imatinib—PDGFRB—uterus—osteoporosis	0.000302	0.0223	CbGeAlD
Imatinib—CSF1R—bone marrow—osteoporosis	0.000289	0.0213	CbGeAlD
Imatinib—ABL1—uterus—osteoporosis	0.000269	0.0198	CbGeAlD
Imatinib—KIT—bone marrow—osteoporosis	0.000262	0.0193	CbGeAlD
Imatinib—PDGFRB—bone marrow—osteoporosis	0.000256	0.0189	CbGeAlD
Imatinib—ORM1—bone marrow—osteoporosis	0.00024	0.0177	CbGeAlD
Imatinib—CA1—bone marrow—osteoporosis	0.00024	0.0177	CbGeAlD
Imatinib—ABL1—bone marrow—osteoporosis	0.000228	0.0168	CbGeAlD
Imatinib—ABCG2—uterus—osteoporosis	0.00017	0.0125	CbGeAlD
Imatinib—CA2—bone marrow—osteoporosis	0.000155	0.0115	CbGeAlD
Imatinib—ABCG2—bone marrow—osteoporosis	0.000144	0.0106	CbGeAlD
Imatinib—PTGS1—uterus—osteoporosis	0.000141	0.0104	CbGeAlD
Imatinib—ABCB1—uterus—osteoporosis	8.36e-05	0.00617	CbGeAlD
Imatinib—ABCB1—bone marrow—osteoporosis	7.09e-05	0.00524	CbGeAlD
Imatinib—Dry mouth—Zoledronate—osteoporosis	6.69e-05	0.000409	CcSEcCtD
Imatinib—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	6.69e-05	0.000409	CcSEcCtD
Imatinib—Fatigue—Ethinyl Estradiol—osteoporosis	6.68e-05	0.000409	CcSEcCtD
Imatinib—Pruritus—Alendronate—osteoporosis	6.66e-05	0.000407	CcSEcCtD
Imatinib—Dyspepsia—Risedronate—osteoporosis	6.65e-05	0.000407	CcSEcCtD
Imatinib—Eye disorder—Estradiol—osteoporosis	6.65e-05	0.000407	CcSEcCtD
Imatinib—Tinnitus—Estradiol—osteoporosis	6.63e-05	0.000406	CcSEcCtD
Imatinib—Constipation—Ethinyl Estradiol—osteoporosis	6.62e-05	0.000405	CcSEcCtD
Imatinib—Confusional state—Zoledronate—osteoporosis	6.61e-05	0.000405	CcSEcCtD
Imatinib—Hypersensitivity—Calcitriol—osteoporosis	6.61e-05	0.000404	CcSEcCtD
Imatinib—Flushing—Estradiol—osteoporosis	6.6e-05	0.000404	CcSEcCtD
Imatinib—Cardiac disorder—Estradiol—osteoporosis	6.6e-05	0.000404	CcSEcCtD
Imatinib—Arthralgia—Conjugated Estrogens—osteoporosis	6.59e-05	0.000403	CcSEcCtD
Imatinib—Chest pain—Conjugated Estrogens—osteoporosis	6.59e-05	0.000403	CcSEcCtD
Imatinib—Myalgia—Conjugated Estrogens—osteoporosis	6.59e-05	0.000403	CcSEcCtD
Imatinib—Asthenia—Ibandronate—osteoporosis	6.57e-05	0.000402	CcSEcCtD
Imatinib—Anxiety—Conjugated Estrogens—osteoporosis	6.56e-05	0.000402	CcSEcCtD
Imatinib—Nausea—Etidronic acid—osteoporosis	6.56e-05	0.000401	CcSEcCtD
Imatinib—Oedema—Zoledronate—osteoporosis	6.56e-05	0.000401	CcSEcCtD
Imatinib—Anaphylactic shock—Zoledronate—osteoporosis	6.56e-05	0.000401	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	6.54e-05	0.0004	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Pamidronate—osteoporosis	6.54e-05	0.0004	CcSEcCtD
Imatinib—Diarrhoea—Estropipate—osteoporosis	6.54e-05	0.0004	CcSEcCtD
Imatinib—Gastrointestinal disorder—Risedronate—osteoporosis	6.52e-05	0.000399	CcSEcCtD
Imatinib—Infection—Zoledronate—osteoporosis	6.51e-05	0.000399	CcSEcCtD
Imatinib—Fatigue—Risedronate—osteoporosis	6.51e-05	0.000398	CcSEcCtD
Imatinib—Insomnia—Pamidronate—osteoporosis	6.49e-05	0.000397	CcSEcCtD
Imatinib—Pruritus—Ibandronate—osteoporosis	6.48e-05	0.000397	CcSEcCtD
Imatinib—Pain—Risedronate—osteoporosis	6.46e-05	0.000395	CcSEcCtD
Imatinib—Constipation—Risedronate—osteoporosis	6.46e-05	0.000395	CcSEcCtD
Imatinib—Angiopathy—Estradiol—osteoporosis	6.45e-05	0.000395	CcSEcCtD
Imatinib—Shock—Zoledronate—osteoporosis	6.45e-05	0.000395	CcSEcCtD
Imatinib—Paraesthesia—Pamidronate—osteoporosis	6.45e-05	0.000394	CcSEcCtD
Imatinib—Diarrhoea—Alendronate—osteoporosis	6.44e-05	0.000394	CcSEcCtD
Imatinib—Asthenia—Calcitriol—osteoporosis	6.44e-05	0.000394	CcSEcCtD
Imatinib—Nervous system disorder—Zoledronate—osteoporosis	6.43e-05	0.000393	CcSEcCtD
Imatinib—Immune system disorder—Estradiol—osteoporosis	6.42e-05	0.000393	CcSEcCtD
Imatinib—Thrombocytopenia—Zoledronate—osteoporosis	6.42e-05	0.000393	CcSEcCtD
Imatinib—Mediastinal disorder—Estradiol—osteoporosis	6.41e-05	0.000392	CcSEcCtD
Imatinib—Dyspnoea—Pamidronate—osteoporosis	6.4e-05	0.000392	CcSEcCtD
Imatinib—Tachycardia—Zoledronate—osteoporosis	6.4e-05	0.000392	CcSEcCtD
Imatinib—Feeling abnormal—Ethinyl Estradiol—osteoporosis	6.38e-05	0.000391	CcSEcCtD
Imatinib—Chills—Estradiol—osteoporosis	6.38e-05	0.000391	CcSEcCtD
Imatinib—Somnolence—Pamidronate—osteoporosis	6.38e-05	0.000391	CcSEcCtD
Imatinib—Skin disorder—Zoledronate—osteoporosis	6.37e-05	0.00039	CcSEcCtD
Imatinib—Pruritus—Calcitriol—osteoporosis	6.35e-05	0.000388	CcSEcCtD
Imatinib—Hyperhidrosis—Zoledronate—osteoporosis	6.34e-05	0.000388	CcSEcCtD
Imatinib—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	6.33e-05	0.000388	CcSEcCtD
Imatinib—Diarrhoea—Raloxifene—osteoporosis	6.33e-05	0.000388	CcSEcCtD
Imatinib—Dyspepsia—Pamidronate—osteoporosis	6.32e-05	0.000387	CcSEcCtD
Imatinib—Dizziness—Estropipate—osteoporosis	6.32e-05	0.000387	CcSEcCtD
Imatinib—Anaphylactic shock—Conjugated Estrogens—osteoporosis	6.31e-05	0.000386	CcSEcCtD
Imatinib—Oedema—Conjugated Estrogens—osteoporosis	6.31e-05	0.000386	CcSEcCtD
Imatinib—Alopecia—Estradiol—osteoporosis	6.29e-05	0.000385	CcSEcCtD
Imatinib—Infection—Conjugated Estrogens—osteoporosis	6.27e-05	0.000384	CcSEcCtD
Imatinib—Diarrhoea—Ibandronate—osteoporosis	6.27e-05	0.000384	CcSEcCtD
Imatinib—Anorexia—Zoledronate—osteoporosis	6.25e-05	0.000382	CcSEcCtD
Imatinib—Decreased appetite—Pamidronate—osteoporosis	6.24e-05	0.000382	CcSEcCtD
Imatinib—Mental disorder—Estradiol—osteoporosis	6.23e-05	0.000381	CcSEcCtD
Imatinib—Dizziness—Alendronate—osteoporosis	6.22e-05	0.000381	CcSEcCtD
Imatinib—Shock—Conjugated Estrogens—osteoporosis	6.21e-05	0.00038	CcSEcCtD
Imatinib—Gastrointestinal disorder—Pamidronate—osteoporosis	6.2e-05	0.000379	CcSEcCtD
Imatinib—Nervous system disorder—Conjugated Estrogens—osteoporosis	6.19e-05	0.000379	CcSEcCtD
Imatinib—Malnutrition—Estradiol—osteoporosis	6.19e-05	0.000379	CcSEcCtD
Imatinib—Erythema—Estradiol—osteoporosis	6.19e-05	0.000379	CcSEcCtD
Imatinib—Fatigue—Pamidronate—osteoporosis	6.19e-05	0.000379	CcSEcCtD
Imatinib—Gastrointestinal pain—Risedronate—osteoporosis	6.18e-05	0.000378	CcSEcCtD
Imatinib—Tachycardia—Conjugated Estrogens—osteoporosis	6.16e-05	0.000377	CcSEcCtD
Imatinib—Urticaria—Ethinyl Estradiol—osteoporosis	6.15e-05	0.000377	CcSEcCtD
Imatinib—Constipation—Pamidronate—osteoporosis	6.14e-05	0.000376	CcSEcCtD
Imatinib—Pain—Pamidronate—osteoporosis	6.14e-05	0.000376	CcSEcCtD
Imatinib—Diarrhoea—Calcitriol—osteoporosis	6.14e-05	0.000376	CcSEcCtD
Imatinib—Skin disorder—Conjugated Estrogens—osteoporosis	6.13e-05	0.000375	CcSEcCtD
Imatinib—Hypotension—Zoledronate—osteoporosis	6.13e-05	0.000375	CcSEcCtD
Imatinib—Body temperature increased—Ethinyl Estradiol—osteoporosis	6.12e-05	0.000375	CcSEcCtD
Imatinib—Abdominal pain—Ethinyl Estradiol—osteoporosis	6.12e-05	0.000375	CcSEcCtD
Imatinib—Dizziness—Raloxifene—osteoporosis	6.12e-05	0.000375	CcSEcCtD
Imatinib—Hyperhidrosis—Conjugated Estrogens—osteoporosis	6.1e-05	0.000373	CcSEcCtD
Imatinib—Flatulence—Estradiol—osteoporosis	6.1e-05	0.000373	CcSEcCtD
Imatinib—Vomiting—Estropipate—osteoporosis	6.08e-05	0.000372	CcSEcCtD
Imatinib—Dysgeusia—Estradiol—osteoporosis	6.06e-05	0.000371	CcSEcCtD
Imatinib—Dizziness—Ibandronate—osteoporosis	6.06e-05	0.000371	CcSEcCtD
Imatinib—Rash—Estropipate—osteoporosis	6.03e-05	0.000369	CcSEcCtD
Imatinib—Dermatitis—Estropipate—osteoporosis	6.02e-05	0.000368	CcSEcCtD
Imatinib—Anorexia—Conjugated Estrogens—osteoporosis	6.02e-05	0.000368	CcSEcCtD
Imatinib—Urticaria—Risedronate—osteoporosis	6e-05	0.000367	CcSEcCtD
Imatinib—Back pain—Estradiol—osteoporosis	5.99e-05	0.000366	CcSEcCtD
Imatinib—Headache—Estropipate—osteoporosis	5.99e-05	0.000366	CcSEcCtD
Imatinib—Vomiting—Alendronate—osteoporosis	5.98e-05	0.000366	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Zoledronate—osteoporosis	5.97e-05	0.000366	CcSEcCtD
Imatinib—Abdominal pain—Risedronate—osteoporosis	5.97e-05	0.000365	CcSEcCtD
Imatinib—Body temperature increased—Risedronate—osteoporosis	5.97e-05	0.000365	CcSEcCtD
Imatinib—Muscle spasms—Estradiol—osteoporosis	5.95e-05	0.000364	CcSEcCtD
Imatinib—Rash—Alendronate—osteoporosis	5.93e-05	0.000363	CcSEcCtD
Imatinib—Insomnia—Zoledronate—osteoporosis	5.93e-05	0.000363	CcSEcCtD
Imatinib—Dermatitis—Alendronate—osteoporosis	5.93e-05	0.000363	CcSEcCtD
Imatinib—Feeling abnormal—Pamidronate—osteoporosis	5.92e-05	0.000362	CcSEcCtD
Imatinib—Hypotension—Conjugated Estrogens—osteoporosis	5.9e-05	0.000361	CcSEcCtD
Imatinib—Headache—Alendronate—osteoporosis	5.9e-05	0.000361	CcSEcCtD
Imatinib—Paraesthesia—Zoledronate—osteoporosis	5.89e-05	0.00036	CcSEcCtD
Imatinib—Vomiting—Raloxifene—osteoporosis	5.89e-05	0.00036	CcSEcCtD
Imatinib—Gastrointestinal pain—Pamidronate—osteoporosis	5.87e-05	0.000359	CcSEcCtD
Imatinib—Dyspnoea—Zoledronate—osteoporosis	5.85e-05	0.000358	CcSEcCtD
Imatinib—Rash—Raloxifene—osteoporosis	5.84e-05	0.000357	CcSEcCtD
Imatinib—Dermatitis—Raloxifene—osteoporosis	5.83e-05	0.000357	CcSEcCtD
Imatinib—Somnolence—Zoledronate—osteoporosis	5.83e-05	0.000357	CcSEcCtD
Imatinib—Vomiting—Ibandronate—osteoporosis	5.83e-05	0.000357	CcSEcCtD
Imatinib—Tremor—Estradiol—osteoporosis	5.8e-05	0.000355	CcSEcCtD
Imatinib—Headache—Raloxifene—osteoporosis	5.8e-05	0.000355	CcSEcCtD
Imatinib—Rash—Ibandronate—osteoporosis	5.78e-05	0.000354	CcSEcCtD
Imatinib—Dermatitis—Ibandronate—osteoporosis	5.77e-05	0.000353	CcSEcCtD
Imatinib—Dyspepsia—Zoledronate—osteoporosis	5.77e-05	0.000353	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	5.75e-05	0.000352	CcSEcCtD
Imatinib—Ill-defined disorder—Estradiol—osteoporosis	5.75e-05	0.000352	CcSEcCtD
Imatinib—Headache—Ibandronate—osteoporosis	5.74e-05	0.000351	CcSEcCtD
Imatinib—Insomnia—Conjugated Estrogens—osteoporosis	5.71e-05	0.000349	CcSEcCtD
Imatinib—Hypersensitivity—Ethinyl Estradiol—osteoporosis	5.71e-05	0.000349	CcSEcCtD
Imatinib—Vomiting—Calcitriol—osteoporosis	5.7e-05	0.000349	CcSEcCtD
Imatinib—Decreased appetite—Zoledronate—osteoporosis	5.7e-05	0.000349	CcSEcCtD
Imatinib—Nausea—Estropipate—osteoporosis	5.68e-05	0.000347	CcSEcCtD
Imatinib—Body temperature increased—Pamidronate—osteoporosis	5.68e-05	0.000347	CcSEcCtD
Imatinib—Abdominal pain—Pamidronate—osteoporosis	5.68e-05	0.000347	CcSEcCtD
Imatinib—Paraesthesia—Conjugated Estrogens—osteoporosis	5.67e-05	0.000347	CcSEcCtD
Imatinib—Gastrointestinal disorder—Zoledronate—osteoporosis	5.66e-05	0.000346	CcSEcCtD
Imatinib—Angioedema—Estradiol—osteoporosis	5.66e-05	0.000346	CcSEcCtD
Imatinib—Rash—Calcitriol—osteoporosis	5.66e-05	0.000346	CcSEcCtD
Imatinib—Fatigue—Zoledronate—osteoporosis	5.65e-05	0.000346	CcSEcCtD
Imatinib—Dermatitis—Calcitriol—osteoporosis	5.65e-05	0.000346	CcSEcCtD
Imatinib—Dyspnoea—Conjugated Estrogens—osteoporosis	5.63e-05	0.000344	CcSEcCtD
Imatinib—Headache—Calcitriol—osteoporosis	5.62e-05	0.000344	CcSEcCtD
Imatinib—Somnolence—Conjugated Estrogens—osteoporosis	5.61e-05	0.000343	CcSEcCtD
Imatinib—Constipation—Zoledronate—osteoporosis	5.61e-05	0.000343	CcSEcCtD
Imatinib—Pain—Zoledronate—osteoporosis	5.61e-05	0.000343	CcSEcCtD
Imatinib—Nausea—Alendronate—osteoporosis	5.59e-05	0.000342	CcSEcCtD
Imatinib—Malaise—Estradiol—osteoporosis	5.58e-05	0.000342	CcSEcCtD
Imatinib—Hypersensitivity—Risedronate—osteoporosis	5.56e-05	0.00034	CcSEcCtD
Imatinib—Vertigo—Estradiol—osteoporosis	5.56e-05	0.00034	CcSEcCtD
Imatinib—Dyspepsia—Conjugated Estrogens—osteoporosis	5.56e-05	0.00034	CcSEcCtD
Imatinib—Asthenia—Ethinyl Estradiol—osteoporosis	5.56e-05	0.00034	CcSEcCtD
Imatinib—Syncope—Estradiol—osteoporosis	5.55e-05	0.00034	CcSEcCtD
Imatinib—Nausea—Raloxifene—osteoporosis	5.5e-05	0.000336	CcSEcCtD
Imatinib—Decreased appetite—Conjugated Estrogens—osteoporosis	5.49e-05	0.000336	CcSEcCtD
Imatinib—Pruritus—Ethinyl Estradiol—osteoporosis	5.48e-05	0.000335	CcSEcCtD
Imatinib—Palpitations—Estradiol—osteoporosis	5.47e-05	0.000335	CcSEcCtD
Imatinib—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	5.45e-05	0.000334	CcSEcCtD
Imatinib—Fatigue—Conjugated Estrogens—osteoporosis	5.44e-05	0.000333	CcSEcCtD
Imatinib—Nausea—Ibandronate—osteoporosis	5.44e-05	0.000333	CcSEcCtD
Imatinib—Loss of consciousness—Estradiol—osteoporosis	5.44e-05	0.000333	CcSEcCtD
Imatinib—Asthenia—Risedronate—osteoporosis	5.42e-05	0.000332	CcSEcCtD
Imatinib—Feeling abnormal—Zoledronate—osteoporosis	5.4e-05	0.000331	CcSEcCtD
Imatinib—Cough—Estradiol—osteoporosis	5.4e-05	0.000331	CcSEcCtD
Imatinib—Pain—Conjugated Estrogens—osteoporosis	5.4e-05	0.00033	CcSEcCtD
Imatinib—Constipation—Conjugated Estrogens—osteoporosis	5.4e-05	0.00033	CcSEcCtD
Imatinib—Gastrointestinal pain—Zoledronate—osteoporosis	5.36e-05	0.000328	CcSEcCtD
Imatinib—Hypertension—Estradiol—osteoporosis	5.35e-05	0.000327	CcSEcCtD
Imatinib—Pruritus—Risedronate—osteoporosis	5.34e-05	0.000327	CcSEcCtD
Imatinib—Nausea—Calcitriol—osteoporosis	5.33e-05	0.000326	CcSEcCtD
Imatinib—Diarrhoea—Ethinyl Estradiol—osteoporosis	5.3e-05	0.000324	CcSEcCtD
Imatinib—Hypersensitivity—Pamidronate—osteoporosis	5.29e-05	0.000324	CcSEcCtD
Imatinib—Arthralgia—Estradiol—osteoporosis	5.27e-05	0.000323	CcSEcCtD
Imatinib—Myalgia—Estradiol—osteoporosis	5.27e-05	0.000323	CcSEcCtD
Imatinib—Chest pain—Estradiol—osteoporosis	5.27e-05	0.000323	CcSEcCtD
Imatinib—Anxiety—Estradiol—osteoporosis	5.25e-05	0.000321	CcSEcCtD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	5.24e-05	0.00032	CcSEcCtD
Imatinib—Urticaria—Zoledronate—osteoporosis	5.21e-05	0.000319	CcSEcCtD
Imatinib—Discomfort—Estradiol—osteoporosis	5.21e-05	0.000319	CcSEcCtD
Imatinib—Abdominal pain—Zoledronate—osteoporosis	5.18e-05	0.000317	CcSEcCtD
Imatinib—Body temperature increased—Zoledronate—osteoporosis	5.18e-05	0.000317	CcSEcCtD
Imatinib—Diarrhoea—Risedronate—osteoporosis	5.17e-05	0.000316	CcSEcCtD
Imatinib—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	5.16e-05	0.000316	CcSEcCtD
Imatinib—Dry mouth—Estradiol—osteoporosis	5.16e-05	0.000315	CcSEcCtD
Imatinib—Asthenia—Pamidronate—osteoporosis	5.15e-05	0.000315	CcSEcCtD
Imatinib—Dizziness—Ethinyl Estradiol—osteoporosis	5.12e-05	0.000313	CcSEcCtD
Imatinib—Confusional state—Estradiol—osteoporosis	5.1e-05	0.000312	CcSEcCtD
Imatinib—Pruritus—Pamidronate—osteoporosis	5.08e-05	0.000311	CcSEcCtD
Imatinib—Oedema—Estradiol—osteoporosis	5.05e-05	0.000309	CcSEcCtD
Imatinib—Anaphylactic shock—Estradiol—osteoporosis	5.05e-05	0.000309	CcSEcCtD
Imatinib—Infection—Estradiol—osteoporosis	5.02e-05	0.000307	CcSEcCtD
Imatinib—Urticaria—Conjugated Estrogens—osteoporosis	5.02e-05	0.000307	CcSEcCtD
Imatinib—Dizziness—Risedronate—osteoporosis	4.99e-05	0.000306	CcSEcCtD
Imatinib—Abdominal pain—Conjugated Estrogens—osteoporosis	4.99e-05	0.000305	CcSEcCtD
Imatinib—Body temperature increased—Conjugated Estrogens—osteoporosis	4.99e-05	0.000305	CcSEcCtD
Imatinib—Shock—Estradiol—osteoporosis	4.97e-05	0.000304	CcSEcCtD
Imatinib—Nervous system disorder—Estradiol—osteoporosis	4.96e-05	0.000303	CcSEcCtD
Imatinib—Tachycardia—Estradiol—osteoporosis	4.93e-05	0.000302	CcSEcCtD
Imatinib—Vomiting—Ethinyl Estradiol—osteoporosis	4.92e-05	0.000301	CcSEcCtD
Imatinib—Diarrhoea—Pamidronate—osteoporosis	4.91e-05	0.000301	CcSEcCtD
Imatinib—Skin disorder—Estradiol—osteoporosis	4.91e-05	0.0003	CcSEcCtD
Imatinib—Hyperhidrosis—Estradiol—osteoporosis	4.89e-05	0.000299	CcSEcCtD
Imatinib—Rash—Ethinyl Estradiol—osteoporosis	4.88e-05	0.000299	CcSEcCtD
Imatinib—Dermatitis—Ethinyl Estradiol—osteoporosis	4.88e-05	0.000299	CcSEcCtD
Imatinib—Headache—Ethinyl Estradiol—osteoporosis	4.85e-05	0.000297	CcSEcCtD
Imatinib—Hypersensitivity—Zoledronate—osteoporosis	4.83e-05	0.000296	CcSEcCtD
Imatinib—Vomiting—Risedronate—osteoporosis	4.8e-05	0.000294	CcSEcCtD
Imatinib—Rash—Risedronate—osteoporosis	4.76e-05	0.000291	CcSEcCtD
Imatinib—Dermatitis—Risedronate—osteoporosis	4.76e-05	0.000291	CcSEcCtD
Imatinib—Dizziness—Pamidronate—osteoporosis	4.75e-05	0.00029	CcSEcCtD
Imatinib—Headache—Risedronate—osteoporosis	4.73e-05	0.000289	CcSEcCtD
Imatinib—Asthenia—Zoledronate—osteoporosis	4.7e-05	0.000288	CcSEcCtD
Imatinib—Hypersensitivity—Conjugated Estrogens—osteoporosis	4.65e-05	0.000285	CcSEcCtD
Imatinib—Pruritus—Zoledronate—osteoporosis	4.64e-05	0.000284	CcSEcCtD
Imatinib—Musculoskeletal discomfort—Estradiol—osteoporosis	4.6e-05	0.000282	CcSEcCtD
Imatinib—Nausea—Ethinyl Estradiol—osteoporosis	4.6e-05	0.000282	CcSEcCtD
Imatinib—Insomnia—Estradiol—osteoporosis	4.57e-05	0.00028	CcSEcCtD
Imatinib—Vomiting—Pamidronate—osteoporosis	4.56e-05	0.000279	CcSEcCtD
Imatinib—Paraesthesia—Estradiol—osteoporosis	4.54e-05	0.000278	CcSEcCtD
Imatinib—Asthenia—Conjugated Estrogens—osteoporosis	4.53e-05	0.000277	CcSEcCtD
Imatinib—Rash—Pamidronate—osteoporosis	4.53e-05	0.000277	CcSEcCtD
Imatinib—Dermatitis—Pamidronate—osteoporosis	4.52e-05	0.000277	CcSEcCtD
Imatinib—Dyspnoea—Estradiol—osteoporosis	4.51e-05	0.000276	CcSEcCtD
Imatinib—Headache—Pamidronate—osteoporosis	4.5e-05	0.000275	CcSEcCtD
Imatinib—Somnolence—Estradiol—osteoporosis	4.49e-05	0.000275	CcSEcCtD
Imatinib—Diarrhoea—Zoledronate—osteoporosis	4.49e-05	0.000275	CcSEcCtD
Imatinib—Nausea—Risedronate—osteoporosis	4.49e-05	0.000274	CcSEcCtD
Imatinib—Pruritus—Conjugated Estrogens—osteoporosis	4.47e-05	0.000273	CcSEcCtD
Imatinib—Dyspepsia—Estradiol—osteoporosis	4.45e-05	0.000272	CcSEcCtD
Imatinib—Decreased appetite—Estradiol—osteoporosis	4.39e-05	0.000269	CcSEcCtD
Imatinib—Gastrointestinal disorder—Estradiol—osteoporosis	4.36e-05	0.000267	CcSEcCtD
Imatinib—Fatigue—Estradiol—osteoporosis	4.36e-05	0.000267	CcSEcCtD
Imatinib—Dizziness—Zoledronate—osteoporosis	4.34e-05	0.000265	CcSEcCtD
Imatinib—Constipation—Estradiol—osteoporosis	4.32e-05	0.000264	CcSEcCtD
Imatinib—Pain—Estradiol—osteoporosis	4.32e-05	0.000264	CcSEcCtD
Imatinib—Diarrhoea—Conjugated Estrogens—osteoporosis	4.32e-05	0.000264	CcSEcCtD
Imatinib—Nausea—Pamidronate—osteoporosis	4.26e-05	0.000261	CcSEcCtD
Imatinib—Dizziness—Conjugated Estrogens—osteoporosis	4.18e-05	0.000255	CcSEcCtD
Imatinib—Vomiting—Zoledronate—osteoporosis	4.17e-05	0.000255	CcSEcCtD
Imatinib—Feeling abnormal—Estradiol—osteoporosis	4.16e-05	0.000255	CcSEcCtD
Imatinib—Rash—Zoledronate—osteoporosis	4.13e-05	0.000253	CcSEcCtD
Imatinib—Gastrointestinal pain—Estradiol—osteoporosis	4.13e-05	0.000253	CcSEcCtD
Imatinib—Dermatitis—Zoledronate—osteoporosis	4.13e-05	0.000253	CcSEcCtD
Imatinib—Headache—Zoledronate—osteoporosis	4.11e-05	0.000251	CcSEcCtD
Imatinib—Vomiting—Conjugated Estrogens—osteoporosis	4.01e-05	0.000246	CcSEcCtD
Imatinib—Urticaria—Estradiol—osteoporosis	4.01e-05	0.000246	CcSEcCtD
Imatinib—Abdominal pain—Estradiol—osteoporosis	3.99e-05	0.000244	CcSEcCtD
Imatinib—Body temperature increased—Estradiol—osteoporosis	3.99e-05	0.000244	CcSEcCtD
Imatinib—Rash—Conjugated Estrogens—osteoporosis	3.98e-05	0.000244	CcSEcCtD
Imatinib—Dermatitis—Conjugated Estrogens—osteoporosis	3.98e-05	0.000243	CcSEcCtD
Imatinib—Headache—Conjugated Estrogens—osteoporosis	3.96e-05	0.000242	CcSEcCtD
Imatinib—Nausea—Zoledronate—osteoporosis	3.9e-05	0.000238	CcSEcCtD
Imatinib—Nausea—Conjugated Estrogens—osteoporosis	3.75e-05	0.000229	CcSEcCtD
Imatinib—Hypersensitivity—Estradiol—osteoporosis	3.72e-05	0.000228	CcSEcCtD
Imatinib—Asthenia—Estradiol—osteoporosis	3.63e-05	0.000222	CcSEcCtD
Imatinib—Pruritus—Estradiol—osteoporosis	3.58e-05	0.000219	CcSEcCtD
Imatinib—Diarrhoea—Estradiol—osteoporosis	3.46e-05	0.000212	CcSEcCtD
Imatinib—Dizziness—Estradiol—osteoporosis	3.34e-05	0.000204	CcSEcCtD
Imatinib—Vomiting—Estradiol—osteoporosis	3.21e-05	0.000197	CcSEcCtD
Imatinib—Rash—Estradiol—osteoporosis	3.19e-05	0.000195	CcSEcCtD
Imatinib—Dermatitis—Estradiol—osteoporosis	3.18e-05	0.000195	CcSEcCtD
Imatinib—Headache—Estradiol—osteoporosis	3.17e-05	0.000194	CcSEcCtD
Imatinib—Nausea—Estradiol—osteoporosis	3e-05	0.000184	CcSEcCtD
Imatinib—KIT—Signaling Pathways—ADCY5—osteoporosis	5.4e-06	5.21e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP27A1—osteoporosis	5.39e-06	5.21e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MGLL—osteoporosis	5.39e-06	5.2e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ACP5—osteoporosis	5.38e-06	5.19e-05	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	5.36e-06	5.18e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—IDH2—osteoporosis	5.36e-06	5.17e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—TNF—osteoporosis	5.34e-06	5.16e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	5.31e-06	5.12e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IRS1—osteoporosis	5.3e-06	5.12e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	5.29e-06	5.11e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6R—osteoporosis	5.29e-06	5.11e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	5.28e-06	5.1e-05	CbGpPWpGaD
Imatinib—LCK—Disease—ADCY5—osteoporosis	5.28e-06	5.09e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ACP5—osteoporosis	5.25e-06	5.07e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—CYP19A1—osteoporosis	5.24e-06	5.06e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6R—osteoporosis	5.24e-06	5.06e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—P4HB—osteoporosis	5.23e-06	5.05e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—SPP1—osteoporosis	5.22e-06	5.04e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IGF1—osteoporosis	5.21e-06	5.03e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CALCA—osteoporosis	5.2e-06	5.02e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—CYP19A1—osteoporosis	5.19e-06	5.01e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—CYP19A1—osteoporosis	5.19e-06	5.01e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GAPDH—osteoporosis	5.14e-06	4.96e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ADCY5—osteoporosis	5.11e-06	4.93e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6R—osteoporosis	5.11e-06	4.93e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP27A1—osteoporosis	5.08e-06	4.91e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	5.08e-06	4.9e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP27A1—osteoporosis	5.04e-06	4.86e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—CYP19A1—osteoporosis	5.03e-06	4.86e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IRS1—osteoporosis	5.02e-06	4.85e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ATIC—osteoporosis	5.02e-06	4.84e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PNP—osteoporosis	5.02e-06	4.84e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—RAP1A—osteoporosis	5e-06	4.83e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IRS2—osteoporosis	5e-06	4.83e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—TPI1—osteoporosis	5e-06	4.82e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6R—osteoporosis	4.98e-06	4.81e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—SPP1—osteoporosis	4.95e-06	4.77e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ACP5—osteoporosis	4.94e-06	4.77e-05	CbGpPWpGaD
Imatinib—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	4.94e-06	4.77e-05	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	4.93e-06	4.76e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ACP5—osteoporosis	4.9e-06	4.73e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—TPI1—osteoporosis	4.88e-06	4.71e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MTHFR—osteoporosis	4.85e-06	4.69e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	4.84e-06	4.67e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—CYP19A1—osteoporosis	4.83e-06	4.67e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IRS2—osteoporosis	4.73e-06	4.56e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6R—osteoporosis	4.72e-06	4.56e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KL—osteoporosis	4.72e-06	4.55e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—P4HB—osteoporosis	4.7e-06	4.54e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ENO1—osteoporosis	4.7e-06	4.53e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PSMA2—osteoporosis	4.63e-06	4.47e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—PSMA5—osteoporosis	4.63e-06	4.47e-05	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TGFB1—osteoporosis	4.62e-06	4.46e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—LEP—osteoporosis	4.62e-06	4.46e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IRS2—osteoporosis	4.62e-06	4.46e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GAPDH—osteoporosis	4.61e-06	4.45e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—IGF1—osteoporosis	4.61e-06	4.45e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ADCY5—osteoporosis	4.61e-06	4.45e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—TPI1—osteoporosis	4.6e-06	4.44e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—P4HB—osteoporosis	4.59e-06	4.43e-05	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—IL6—osteoporosis	4.58e-06	4.42e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—IDH2—osteoporosis	4.58e-06	4.42e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL1B—osteoporosis	4.56e-06	4.4e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—TPI1—osteoporosis	4.56e-06	4.4e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GAPDH—osteoporosis	4.5e-06	4.35e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—RAP1A—osteoporosis	4.49e-06	4.34e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IRS2—osteoporosis	4.47e-06	4.32e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—SPP1—osteoporosis	4.46e-06	4.3e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—ESR1—osteoporosis	4.41e-06	4.26e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—RAP1A—osteoporosis	4.38e-06	4.23e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—LEP—osteoporosis	4.38e-06	4.23e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IRS1—osteoporosis	4.37e-06	4.22e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.36e-06	4.21e-05	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—IL6—osteoporosis	4.34e-06	4.19e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—P4HB—osteoporosis	4.32e-06	4.17e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL1B—osteoporosis	4.32e-06	4.17e-05	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—IL6—osteoporosis	4.31e-06	4.16e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP27A1—osteoporosis	4.31e-06	4.16e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—P4HB—osteoporosis	4.28e-06	4.14e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—ADCY5—osteoporosis	4.28e-06	4.13e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—GPX1—osteoporosis	4.27e-06	4.12e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—OXCT1—osteoporosis	4.27e-06	4.12e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CA2—osteoporosis	4.27e-06	4.12e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—ADCY5—osteoporosis	4.24e-06	4.1e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GAPDH—osteoporosis	4.24e-06	4.1e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—ADCY5—osteoporosis	4.24e-06	4.09e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—GPX1—osteoporosis	4.23e-06	4.08e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—GPX1—osteoporosis	4.22e-06	4.08e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GAPDH—osteoporosis	4.21e-06	4.06e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ACP5—osteoporosis	4.19e-06	4.04e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—ESR1—osteoporosis	4.18e-06	4.03e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MGLL—osteoporosis	4.16e-06	4.01e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	4.14e-06	3.99e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—RAP1A—osteoporosis	4.13e-06	3.99e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IRS1—osteoporosis	4.12e-06	3.98e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—ADCY5—osteoporosis	4.11e-06	3.97e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6R—osteoporosis	4.1e-06	3.96e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—GPX1—osteoporosis	4.1e-06	3.96e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—RAP1A—osteoporosis	4.1e-06	3.95e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—ENO1—osteoporosis	4.04e-06	3.9e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IRS1—osteoporosis	4.03e-06	3.89e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IRS2—osteoporosis	4.03e-06	3.89e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PSMA2—osteoporosis	3.99e-06	3.85e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—PSMA5—osteoporosis	3.99e-06	3.85e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—POMC—osteoporosis	3.97e-06	3.83e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—ADCY5—osteoporosis	3.95e-06	3.81e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—LEP—osteoporosis	3.94e-06	3.81e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—MTHFR—osteoporosis	3.94e-06	3.8e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—GPX1—osteoporosis	3.94e-06	3.8e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.92e-06	3.78e-05	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—IL6—osteoporosis	3.91e-06	3.77e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IRS1—osteoporosis	3.9e-06	3.77e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—MTHFR—osteoporosis	3.9e-06	3.77e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—MTHFR—osteoporosis	3.9e-06	3.76e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—TPI1—osteoporosis	3.89e-06	3.76e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL1B—osteoporosis	3.89e-06	3.75e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6R—osteoporosis	3.87e-06	3.74e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IGF1—osteoporosis	3.82e-06	3.69e-05	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—IL6—osteoporosis	3.81e-06	3.68e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL1B—osteoporosis	3.79e-06	3.66e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IL6R—osteoporosis	3.79e-06	3.66e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—MTHFR—osteoporosis	3.78e-06	3.65e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—ESR1—osteoporosis	3.76e-06	3.63e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—POMC—osteoporosis	3.76e-06	3.63e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—CYP19A1—osteoporosis	3.75e-06	3.62e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ADCY5—osteoporosis	3.7e-06	3.57e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6R—osteoporosis	3.67e-06	3.54e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—P4HB—osteoporosis	3.66e-06	3.53e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—MTHFR—osteoporosis	3.63e-06	3.51e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ENO1—osteoporosis	3.63e-06	3.51e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IGF1—osteoporosis	3.62e-06	3.49e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GAPDH—osteoporosis	3.59e-06	3.47e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PSMA5—osteoporosis	3.58e-06	3.45e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—PSMA2—osteoporosis	3.58e-06	3.45e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—SPP1—osteoporosis	3.58e-06	3.45e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.57e-06	3.45e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ENO1—osteoporosis	3.54e-06	3.42e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—IDH2—osteoporosis	3.53e-06	3.41e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IRS1—osteoporosis	3.52e-06	3.4e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—RAP1A—osteoporosis	3.5e-06	3.38e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PSMA2—osteoporosis	3.49e-06	3.37e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—PSMA5—osteoporosis	3.49e-06	3.37e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—POMC—osteoporosis	3.39e-06	3.27e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ENO1—osteoporosis	3.34e-06	3.22e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP27A1—osteoporosis	3.32e-06	3.21e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ENO1—osteoporosis	3.31e-06	3.2e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6R—osteoporosis	3.3e-06	3.19e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PSMA2—osteoporosis	3.29e-06	3.18e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—PSMA5—osteoporosis	3.29e-06	3.18e-05	CbGpPWpGaD
Imatinib—KIT—Disease—MYC—osteoporosis	3.28e-06	3.17e-05	CbGpPWpGaD
Imatinib—KIT—Disease—TGFB1—osteoporosis	3.27e-06	3.16e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PSMA2—osteoporosis	3.26e-06	3.15e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—PSMA5—osteoporosis	3.26e-06	3.15e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IGF1—osteoporosis	3.26e-06	3.15e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—CYP19A1—osteoporosis	3.23e-06	3.12e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IRS2—osteoporosis	3.23e-06	3.12e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ACP5—osteoporosis	3.23e-06	3.12e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—LEP—osteoporosis	3.16e-06	3.05e-05	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—POMC—osteoporosis	3.15e-06	3.04e-05	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—IL6—osteoporosis	3.14e-06	3.03e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MYC—osteoporosis	3.13e-06	3.03e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TGFB1—osteoporosis	3.13e-06	3.02e-05	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—POMC—osteoporosis	3.12e-06	3.01e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL1B—osteoporosis	3.12e-06	3.01e-05	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—POMC—osteoporosis	3.12e-06	3.01e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MYC—osteoporosis	3.1e-06	3e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—TGFB1—osteoporosis	3.1e-06	2.99e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—ADCY5—osteoporosis	3.07e-06	2.96e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—GPX1—osteoporosis	3.06e-06	2.95e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	3.05e-06	2.95e-05	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—POMC—osteoporosis	3.03e-06	2.92e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—ESR1—osteoporosis	3.02e-06	2.92e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—TPI1—osteoporosis	3.01e-06	2.9e-05	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—POMC—osteoporosis	2.91e-06	2.8e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—CYP19A1—osteoporosis	2.9e-06	2.8e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—CYP19A1—osteoporosis	2.83e-06	2.74e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ENO1—osteoporosis	2.83e-06	2.73e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—P4HB—osteoporosis	2.83e-06	2.73e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IRS1—osteoporosis	2.82e-06	2.73e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—MTHFR—osteoporosis	2.82e-06	2.72e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MYC—osteoporosis	2.8e-06	2.7e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—TGFB1—osteoporosis	2.79e-06	2.69e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PSMA2—osteoporosis	2.79e-06	2.69e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—PSMA5—osteoporosis	2.79e-06	2.69e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GAPDH—osteoporosis	2.77e-06	2.68e-05	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TGFB1—osteoporosis	2.76e-06	2.67e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—POMC—osteoporosis	2.72e-06	2.62e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—RAP1A—osteoporosis	2.7e-06	2.61e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—CYP19A1—osteoporosis	2.67e-06	2.58e-05	CbGpPWpGaD
Imatinib—KIT—Immune System—IL6—osteoporosis	2.67e-06	2.58e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6R—osteoporosis	2.65e-06	2.56e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—CYP19A1—osteoporosis	2.65e-06	2.56e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—ADCY5—osteoporosis	2.64e-06	2.55e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—GPX1—osteoporosis	2.63e-06	2.54e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IGF1—osteoporosis	2.61e-06	2.52e-05	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL6—osteoporosis	2.53e-06	2.44e-05	CbGpPWpGaD
Imatinib—KIT—Disease—IL6—osteoporosis	2.46e-06	2.38e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—MTHFR—osteoporosis	2.43e-06	2.35e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—ADCY5—osteoporosis	2.37e-06	2.29e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—GPX1—osteoporosis	2.36e-06	2.28e-05	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL6—osteoporosis	2.36e-06	2.27e-05	CbGpPWpGaD
Imatinib—PDGFRA—Disease—IL6—osteoporosis	2.33e-06	2.25e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—ADCY5—osteoporosis	2.32e-06	2.23e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—GPX1—osteoporosis	2.31e-06	2.23e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MYC—osteoporosis	2.3e-06	2.22e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TGFB1—osteoporosis	2.29e-06	2.21e-05	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL6—osteoporosis	2.28e-06	2.2e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—CYP19A1—osteoporosis	2.26e-06	2.18e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—POMC—osteoporosis	2.26e-06	2.18e-05	CbGpPWpGaD
Imatinib—LCK—Disease—MYC—osteoporosis	2.24e-06	2.17e-05	CbGpPWpGaD
Imatinib—LCK—Disease—TGFB1—osteoporosis	2.24e-06	2.16e-05	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL6—osteoporosis	2.22e-06	2.14e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ENO1—osteoporosis	2.18e-06	2.11e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—ADCY5—osteoporosis	2.18e-06	2.11e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—MTHFR—osteoporosis	2.18e-06	2.11e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—GPX1—osteoporosis	2.17e-06	2.1e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MYC—osteoporosis	2.17e-06	2.1e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TGFB1—osteoporosis	2.17e-06	2.09e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—ADCY5—osteoporosis	2.16e-06	2.09e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—GPX1—osteoporosis	2.16e-06	2.08e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PSMA5—osteoporosis	2.15e-06	2.08e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—PSMA2—osteoporosis	2.15e-06	2.08e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—MTHFR—osteoporosis	2.13e-06	2.06e-05	CbGpPWpGaD
Imatinib—PDGFRB—Disease—IL6—osteoporosis	2.1e-06	2.03e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—MTHFR—osteoporosis	2.01e-06	1.94e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—MTHFR—osteoporosis	1.99e-06	1.92e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MYC—osteoporosis	1.96e-06	1.89e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TGFB1—osteoporosis	1.95e-06	1.89e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—POMC—osteoporosis	1.94e-06	1.88e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—ADCY5—osteoporosis	1.85e-06	1.78e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—GPX1—osteoporosis	1.84e-06	1.78e-05	CbGpPWpGaD
Imatinib—LCK—Immune System—IL6—osteoporosis	1.83e-06	1.76e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—CYP19A1—osteoporosis	1.75e-06	1.69e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—POMC—osteoporosis	1.74e-06	1.68e-05	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL6—osteoporosis	1.73e-06	1.67e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—POMC—osteoporosis	1.7e-06	1.64e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—MTHFR—osteoporosis	1.7e-06	1.64e-05	CbGpPWpGaD
Imatinib—LCK—Disease—IL6—osteoporosis	1.69e-06	1.63e-05	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL6—osteoporosis	1.63e-06	1.58e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—POMC—osteoporosis	1.6e-06	1.55e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—POMC—osteoporosis	1.59e-06	1.54e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MYC—osteoporosis	1.57e-06	1.52e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TGFB1—osteoporosis	1.57e-06	1.51e-05	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL6—osteoporosis	1.47e-06	1.42e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—ADCY5—osteoporosis	1.43e-06	1.38e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—GPX1—osteoporosis	1.42e-06	1.37e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—POMC—osteoporosis	1.36e-06	1.31e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—MTHFR—osteoporosis	1.31e-06	1.27e-05	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL6—osteoporosis	1.18e-06	1.14e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—POMC—osteoporosis	1.05e-06	1.01e-05	CbGpPWpGaD
